Test directory: 14-3-3 protein

Ordering Code7882
Test Name14-3-3 protein
Alias14-3-3
T-tau protein
RT-QuIC
prion
CJD
Creutzfeldt-Jakob
Preferred SpecimenCerebral Spinal Fluid
Preferred ContainerCerebral Spinal Fluid Kit Tubes
Optimum Volume5 mL
Collection InstructionsDiscard first 2 mL of CSF from the tap. Collect 2-5 mL clear +colorless CSF and freeze immediately at -20 to -80 degrees C
Case Western form must be completed by the client: https://case.edu/medicine/pathology/sites/case.edu
pathology/files/2023-10/Test%20Request%20Form.pdf
Transport RequirementsOahu: Frozen
Airline: Frozen
Specimen StabilityAmbient: 24 Hours
Refrigerated: 14 Days
Frozen: Indefinite
Rejection CriteriaBloody CSF cannot be accurately tested
Avail. StatNO
Analytic Time10 Days
MethodologyImmunoassay;
Real-time quaking-induced conversion (RT-QuIC)
Reference Lab Nat'l Prion Disease Surveillance Ctr

Reference range(s)

The reference ranges listed below are valid on this date of November 21, 2024.
ComponentAgeMale NormMale Critical LowMale Critical HighFemale NormFemale Critical HighFemale Critical LowUnitsAdd'l info
RT-QuIC (CSF)ALLNEGATIVENEGATIVE
RT-QuIC identifies... RT-QuIC identifies the disease-causing agent
Note1
T-Tau protein (CSF)ALL0-11490-1149pg/mL
14-3-3 GAMMA (CSF)ALL173-1999173-1999AU/mL
T-tau protein and 14... T-tau protein and 14-3-3 GAMMA are indirect markers of neurodegenerative disease.
Note2
Likelihood of prion diseaseALL%

This test was...
This test was developed and its performance characteristics determined by the National Prion
Disease Pathology and Surveillance Center
Clinical Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration
The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. These assays should be used in conjunction with other clinical, pathological and laboratory findings
This laboratory is certified under the Clinical
Laboratory Improvement Amendments (CLIA) as qualified to perform clinical laboratory testing

See report.
Note3

Note1:

RT-QuIC identifies the disease-causing agent.

Note2:

T-tau protein and 14-3-3 GAMMA are indirect markers of neurodegenerative disease..

Note3:


This test was developed and its performance characteristics determined by the National Prion
Disease Pathology and Surveillance Center
Clinical Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration
The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. These assays should be used in conjunction with other clinical, pathological and laboratory findings
This laboratory is certified under the Clinical
Laboratory Improvement Amendments (CLIA) as qualified to perform clinical laboratory testing

See report..